Long title
A phase III, multicenter, randomized, open-label study to compare the efficacy and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
Date receipt dossier
EU record number
68284528MMY2001
EudraCT number
2018-001023-38
Company / Sponsor
Celgene
Phase
III
Treated organism
Humans
Indication category
Cancer therapy
Disease
relapsed or refractory multiple myeloma
Therapeutic approach
Immunotherapy
Genetic modification
BCMA02 (human B cell maturation antigen) -Chimeric antigen receptor
Method of transfer of nucleic acid of interest
Lentiviral vectors
Administered biological material
Autologous T-cells transduced with lentiviral vectors expressing BCMA02 (human B cell maturation antigen)-chimeric antigen receptor
Route of administration
Intravenous
Locations in Belgium
UZ Leuven
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
bb2121